Comparing cemacabtagene ansegedleucel with Foresight CLARITY™ IUO MRD test, for large b-cell lymphoma
Explore this study →
There are 2 groups in this study. Group A receives cemacabtagene ansegedleucel, together with one or more of: Fludarabine, Cyclophosphamide and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™. Group B receives Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™.
Sites in Montreal, Calgary and 3 more cities
- Phase 2
- 2 groups
- Sites in Calgary, Halifax and 3 more cities
- Recruiting
Official title: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma · Allogene Therapeutics